ArticleCurrent medical science2025
Salidroside Enhances the Sensitivity of Lung Cancer Cells to Paclitaxel by Regulating the Wnt/β-catenin Signaling Pathway.
Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salidroside-Based Nanomedicines for Triple-Negative Breast Cancer: From Molecular Mechanisms to Clinical Translation.Breast cancer (Dove Medical Press) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChemoresistance, such as paclitaxel (PTX) resistance, has become a great obstacle in non-small cell lung cancer (NSCLC) treatment. The natural agent salidroside (SAL) has been shown to exert an antitumor effect on NSCLC. Nonetheless, it is unclear whether SAL can decrease the resistance of NSCLC to PTX.
methodsPTX-resistant NSCLC cells (H1299/PTX and A549/PTX) were generated. Cell Counting Kit-8 (CCK-8) assay was used to detect cell viability. Colony formation assay and flow cytometry were utilized to assess cell proliferation and apoptosis, respectively. Immunofluorescence staining and TOP/FOP flash luciferase assay were employed to estimate β-catenin activation. Western blotting was implemented to estimate the protein levels of apoptosis-, proliferation-, and Wnt/β-catenin signaling-associated markers. A xenograft mouse model was established to investigate the impact of SAL on PTX resistance in vivo.
resultsSAL increased PTX-induced suppression of proliferation and promoted apoptosis in PTX-resistant NSCLC cells. SAL blocked the Wnt/β-catenin signaling in A549/PTX cells and in tumor-bearing mice. Activating Wnt/β-catenin signaling reversed the SAL-mediated increase in the sensitivity of NSCLC cells to PTX. SAL attenuated PTX resistance in NSCLC in the xenograft mouse model.
conclusionSAL enhances the sensitivity of NSCLC cells to PTX by blocking the Wnt/β-catenin signal transduction.
Indexed as
Identifiers
40014194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.